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Introduction
Endometrial Hyperplasia (EH) is a condition that is characterised 
by abnormal growth of the endometrium lining the uterus [1-3]. 
This condition is more prevalent among peri-menopausal and post-
menopausal women [4]. While previously EH was classified into simple 
or complex EH, with or without atypia [2], the 2014 World Health 
Organisation classification simplifies this into EH without atypia and 
atypical hyperplasia [5]. Atypical hyperplasia is less common than other 
types, and results from observational studies suggest that it is the type 
which is more associated with the risk of progression to endometrial 
cancer [1-3]. The endometrial cancers which develop from EH are so-
called type 1 endometrial cancers of endometrioid type [6]. 
The risk of progression for EH to endometrial cancer has been 
reported from a large population-based nested case-control study 
including 7,947 enrolees at a prepaid health plan in the USA. In that 
study, atypical EH was associated with a 14-fold increased risk of 
endometrial cancer, while the risk of progression for simple EH and 
complex (non-atypical) EH were significantly lower [7].
Given the potential for neoplastic progression, treatment options 
for EH include hysterectomy, and hormonal therapies; occasionally 
‘watchful waiting’ is adopted for EH without atypia [8]. The need for 
such interventions, and potential psychological distress for women 
following an EH diagnosis [9]. highlight the importance of preventing 
EH where possible. Identification of modifiable risk factors for EH 
would enable women to make lifestyle changes that could reduce risk 
of this condition, and subsequent cancer risk [10]. EH, especially EH 
without atypia, develops as a consequence of excessive or prolonged 
exposure to oestrogen [11-13], and an imbalance between oestrogen 
and progesterone levels which usually occur as a result of insufficient 
progesterone in comparison with oestrogen level in a woman’s 
system [13], For premenopausal women, the balance between these 
hormones changes during a woman’s menstrual cycle each month. 
After menopause, the ovaries stop producing these hormones, but a 
small amount of oestrogen can be synthesized from androgen by the 
Abstract
To conduct a systematic review of risk factors associated with the development of Endometrial Hyperplasia (EH).
Data sources
Ovid MEDLINE, EMBASE and Web of Science databases were searched from inception to 30 June 2015. 
Study eligibility
Fifteen observational studies that reported on EH risk in relation to lifestyle factors (n=14), medical history (n=11), 
reproductive and menstrual history (n=9) and measures of socio-economic status (n=2) were identified. Pooled relative 
risk estimates and corresponding 95% confidence intervals (CI) were able to be derived for EH and Body Mass Index 
(BMI), smoking, diabetes and hypertension, using random effects models comparing high versus low categories.
Results
The pooled relative risk for EH when comparing women with the highest versus lowest BMI was 1.82 (95% CI 
1.22–2.71; n=7 studies, I2=90.4%). No significant associations were observed for EH risk for smokers compared 
with non-smokers (RR 0.88, 95% CI 0.66-1.17; n=3, I2=0.0%), hypertensive versus normotensive women (RR 1.51, 
95% CI 0.72–3.15; n=5 studies, I2=79.1%), or diabetic versus non-diabetic women (RR 1.77, 95% CI 0.79–3.96; n=5 
studies, I2=31.8%) respectively although the number of included studies was limited. There were mixed reports on the 
relationship between age and risk of EH. Too few studies reported on other factors to reach any conclusions in relation 
to EH risk. 
Conclusions
A high BMI was associated with an increased risk of EH, providing additional rationale for women to maintain a 
normal body weight. No significant associations were detected for other factors and EH risk, however relatively few 
studies have been conducted and few of the available studies adequately adjusted for relevant confounders. Therefore, 
further aetiological studies of endometrial hyperplasia are warranted.
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enzyme aromatase [14]. Given the predominant role of hormones 
in the development of EH, a Cochrane review on hormone therapy 
in postmenopausal women which included 45 trials and 38,702 
participants found that unopposed oestrogen is associated with an 
increased risk of EH with relative risks of 3.20 (95% CI 2.02 – 5.26) and 
10.09 (95% CI 4.90 – 20.80) for moderate and high doses of oestrogen 
respectively, although this increased risk was not observed with low 
doses of hormone replacement therapy (HRT) use [13].
Similar to known risk factors for endometrial cancer [15], it is 
possible that demographic and modifiable factors such as age, parity, 
oral contraceptive use, body fatness, physical activity, smoking and 
co-morbidities may play an aetiological role in the development of EH 
[1,12,16]. The aim of this systematic review and meta-analyses is to 
quantify the association between risk factors (excluding HRT, since this 
is incorporated in a Cochrane review 13 and development of EH.
Materials and Methods
Search strategy
Three electronic databases namely MEDLINE (US National Library 
of Medicine, Bethesda, Maryland), EMBASE (Reed Elsevier PLC, 
Amsterdam, Netherlands), and Web of Science (Thomson Reuters, 
USA) were systematically searched from inception up to 30 June 2015 
for relevant studies that included one or more keyword(s) or Medical 
Subject Heading from each of the following groups of terms:
(i) endometrial hyperplasia, simple endometrial hyperplasia, 
complex endometrial hyperplasia, complex hyperplasia with atypia, 
simple hyperplasia with atypia, complex atypical endometrial 
hyperplasia, simple atypical endometrial hyperplasia;
(ii) risk factor(s), causality, association, predisposing factor(s), pre-
disposing factor(s), parity, obesity, history of diabetes, ethnicity, race, 
socio-economic status, occupation, education, oral contraceptive use, 
tamoxifen use, NSAID use, aspirin use, age at first birth, miscarriage 
history, age at menarche, alcohol, smoking, PCOS, polycystic ovarian 
syndrome, family history of cancer, personal history of cancer, 
medications, BMI, body mass index, waist circumference, body weight, 
diet, body fatness, waist-hip ratio, physical activity, use of fertility 
treatments. 
 Review articles and animal studies were excluded and no language 
restriction was applied.
Data extraction
Titles and abstracts for potentially relevant articles were 
independently screened by two of three reviewers (OS, LM and HC). 
Then two reviewers (OS and HC) independently screened full text 
articles for the remaining studies to identify relevant studies that meet 
the pre-set inclusion criteria for the systematic review:
(i) Participants: Women aged 18 and above.
(ii) Interventions: Measurement of risk factors (excluding HRT) 
in the study population.
(iii) Comparators: Women without a diagnosis of EH.
(iv) Outcome: Risk of EH.
The full text of the remaining articles were independently screened 
by two reviewers (OS and HC) to identify relevant studies that meet the 
pre-set inclusion criteria for the systematic review. Articles reporting on 
less than 10 cases of EH were excluded from the review. Meetings were 
held between three reviewers (LJ, HC, OS) to resolve any discrepancies. 
The full protocol for this review can be found at http://www.crd.
york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016569#.
VRfpRJMe5ME. Relevant information about study design, number of 
cases, controls or cohort size, menopausal status of the study population, 
age, and method used to diagnose EH, control definition, method used 
to measure exposure and adjusted confounders were extracted from 
full text articles. The Newcastle Ottawa Scale coding manual was used 
to assess quality of each study. Some studies reported EH risk as part 
of a combined EH and endometrial cancer risk estimate, and were 
retained for inclusion in the systematic review, and sensitivity analysis 
conducted removing such studies from overall pooled estimates. 
Studies that compared risk between different types of EH, and not 
in comparison with a true control group that did not have EH, were 
excluded. Attempts were made to retrieve additional information where 
required from a number of authors via e-mail contact [17-22].
Statistical analysis
Statistical analyses were conducted with STATA version 13 
(StataCorp, College Station, TX, USA). Unadjusted and maximally 
adjusted relative risk (RR) estimates and corresponding 95% confidence 
intervals (CI) were extracted from published articles where possible. 
Random-effects models were used to derive pooled RRs [23] and CI. 
It was decided a priori to perform meta-analyses where at least three 
studies had reported risk estimates for a particular risk factor. When 
applying these criteria we were able to conduct meta-analyses of EH 
risk comparing high versus low for body mass index (BMI), smoking, 
hypertension, and diabetes.
Sensitivity analyses were conducted for EH risk in relation to BMI 
and diabetes removing individual studies; this was not possible for 
other risk factors as too few studies reported these. Sub-group analysis 
was performed where possible for EH with or without atypia in relation 
to BMI, diabetes and hypertension. We also assessed heterogeneity 
of studies included in meta-analyses using the I2 statistic [24,25]; I2 
values of 25%, 50% and 75% are typically interpreted as low, moderate 
and high heterogeneity respectively. We investigated the likelihood 
of publication bias using the Egger’s test [26,27]. Combined RR were 
calculated before entry into final meta-analyses for studies that reported 
separate EH risk estimates only by different types of EH or different age 
categories. Specifically, one study reported separate EH risk estimates 
for complex EH and atypical EH [28].
Results
After application of our search strategy in the three databases, 
and removal of duplicates, a total of 2,890 titles and abstracts were 
reviewed in the first instance to determine potentially relevant studies 
for inclusion. After title and abstract review, 79 full text articles and 
abstracts were reviewed, and 15 full text articles were retained in the 
review (Figure 1). Included articles assessed lifestyle factors, menstrual 
history, age, medical history, reproductive history and socio-economic 
factors and their relationship with risk of developing EH. 
Lifestyle factors
BMI
Eight studies examined BMI and risk of EH [12,28-34]. Four were 
case-control studies [12,28,30,32], two were cohort studies [31,34] 
and two were cross-sectional studies [29,33]. Characteristics of these 
studies are fully described in Table 1.
Six studies [12,28,29,32-34] provided or allowed unadjusted RRs 
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Potentially relevant papers identified 
through search of MEDLINE (n = 926) 
Potentially relevant papers identified 
through search of EMBASE (n = 1721) 
Potentially relevant papers identified through 
search of WEB OF SCIENCE (n = 1350) 
Number of titles and abstracts assessed for eligibility, after removal of duplicates     
(n= 2890 ) 
Number of full text articles assessed for eligibility (n=79) 
Number of articles included in systematic review after application of exclusion criteria 
(n= 15); comprising 
Lifestyle factors (n=14)* 
BMI = 8 
Body weight = 1 
Quetelet index = 1 
Smoking = 3 
Physical activity = 1 
Medical history (n = 8)* 
Diabetes = 5 
Hypertension = 4 
History of cancer = 2 
Reproductive factors and Menstrual history (n = 8)* 
Oral contraceptives use = 2 
Parity = 4 
Menopausal status = 2 
Intermenstrual interval = 1 
Other  
Education and Income = 2 
Age = 2 
 
Reasons for exclusion (n=64):  
Less than 10 cases of EH = 9 
Review article = 2 
Duplicate report = 3 
EH risk not assessed = 31 
No comparison/control group = 15 
Only HRT use assessed as risk factor = 1 
Article could not be retrieved = 3 
 
Figure 1: Flow diagram of study selection.
to be calculated, and the pooled RR for EH when comparing women 
with the highest versus lowest BMI was 1.84 (95%CI: 1.18-2.88) with 
I2 62.9%. Results from seven studies [12,28-31,33,34] were pooled to 
derive maximally adjusted EH risk estimates for the highest versus 
the lowest category of BMI. As shown in Figure 2, high BMI was 
significantly associated with an increased EH risk (RR 1.82, 95%CI: 
1.22-2.71) with an I2 of 90.4%. Egger’s test showed no significant 
evidence of publication bias (p=0.18). Heterogeneity remained 
consistently high after removal of individual studies, this may be due 
to the variability of adjusted confounders across studies (Table 2). Only 
the exclusion of Balbi et al. [30] reduced heterogeneity somewhat and 
markedly affected results. This study investigated simple EH risk only, 
and sub-group analysis between BMI and EH without atypia resulted 
in a non-significant positive association (RR 1.27, 95%CI 0.49-3.59) 
(Table 3). 
Other body fatness measures
Two studies have investigated other body fatness measures and EH 
risk, as summarised in Tables 1 and  
One study among premenopausal women with abnormal menstrual 
bleeding reported a significant 7–fold increased risk for complex 
atypical EH and endometrial carcinoma combined (OR 7.3, 95%CI 
3.2–16.8), comparing body weight >90kg versus <90kg [35].
In a further study, the Quetelet index was reported to be significantly 
higher in postmenopausal EH cases, compared with controls, leading to 
an increased risk (OR 3.8, 95%CI 1.27–11.40) when comparing >2.9 
versus ≤2.9. In contrast, a protective effect for premenopausal women 
was noted (OR 0.25, 95% CI 0.07–0.95) [36]. 
Smoking
Two population-based [28,37,38] and one hospital-based 12 case-
control studies examined the relationship between smoking and risk of 
EH. Descriptions of study characteristics are shown in Table 4. 
Results from these three studies were pooled to derive an unadjusted 
EH risk estimate of 0.98 (95%CI 0.64-1.49) with I2 45.7% for smokers 
compared with non-smokers. Adjusted pooled risk estimate was 0.88 
(95%CI 0.66-1.17) with 0% heterogeneity for smokers when compared 
with non-smokers (Figure 3).
The moderate heterogeneity among studies disappeared after 
adjusting for confounders. However, only one study adjusted for HRT, 
and two adjusted for BMI as shown in Table 4.
Physical activity
One Italian hospital-based case-control study 30 reported non-
significant increased risk of EH (OR 1.38 95%CI 0.50–3.77) among 
women who reported high levels of physical activity (≥60 minutes 3 
times/week) when compared with those who reported lower levels of 
physical activity (Tables 1 and 4).
Medical history
Diabetes
Five studies evaluated the relationship between diabetes and EH 
risk. Three were hospital-based case-control [12,30,34], one was a 
population-based case-control,28 and one was a prospective cohort 
study [39]. Characteristics of the studies are shown in Table 5.
Three studies [12,28,38] were included in meta-analysis in order 
to derive unadjusted pooled EH risk estimate for diabetic versus 
Citation: Sanni OB, Kunzmann AT, Murray LJ, McCluggage WG, Coleman HG (2016) Risk Factors (Excluding Hormone Replacement Therapy) for 
Endometrial Hyperplasia: A Systematic Review. Epidemiol 6: 229. doi:10.4172/2161-1165.1000229
Page 4 of 15
Volume 6 • Issue 2 • 1000229
Epidemiol
ISSN: 2161-1165 Epidemiol, an open access journal
A
ut
ho
r, 
Ye
ar
, 
Lo
ca
tio
n
St
ud
y 
de
si
gn
N
o.
 
C
as
es
N
o.
 
C
on
tr
ol
s/
co
ho
rt
 
si
ze
M
en
op
au
sa
l 
st
at
us
A
ge
, y
ea
rs
 
(r
an
ge
) 
C
as
es
/ 
C
on
tr
ol
s
C
as
e 
de
fin
iti
on
 
in
cl
ud
in
g 
EH
 ty
pe
M
et
ho
d 
of
 
di
ag
no
si
s
C
on
tr
ol
 d
efi
ni
tio
n
M
et
ho
d 
of
 
m
ea
su
rin
g 
bo
dy
 fa
tn
es
s
A
dj
us
te
d 
co
nf
ou
nd
er
s
Q
ua
lit
y 
sc
al
e 
sc
or
e 
(m
ax
. 9
)
B
od
y 
M
as
s 
In
de
x 
  
B
al
bi
 e
t a
l. 
(2
01
2)
 [2
9]
,  
 
Ita
ly
H
os
pi
ta
l-b
as
ed
 
ca
se
-c
on
tro
l
16
7
28
2
P
re
-m
en
op
au
sa
l
40
-5
5
S
im
pl
e 
E
H
C
on
fir
m
ed
 b
y 
 1
 
pa
th
ol
og
is
t
W
om
en
 a
tte
nd
in
g 
gy
na
ec
ol
og
ic
 u
ni
t 
of
 2
 h
os
pi
ta
ls
 
fo
r m
en
st
ru
al
 
irr
eg
ul
ar
iti
es
In
te
rv
ie
w
, 
m
ed
ic
al
 h
is
to
ry
, 
ge
ne
ra
l p
hy
si
ca
l 
ex
am
in
at
io
n
A
ge
, h
yp
er
te
ns
io
n,
 
di
ab
et
es
, p
hy
si
ca
l 
ac
tiv
ity
7
C
he
un
g 
et
 a
l. 
(2
00
1)
 [3
0]
, 
C
an
ad
a
C
as
e-
co
nt
ro
l
45
36
P
re
-m
en
op
au
sa
l
23
-4
1/
21
-3
9
S
im
pl
e 
or
 c
om
pl
ex
 
E
H
 w
ith
 o
r w
ith
ou
t 
at
yp
ia
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
 b
y 
pa
th
ol
og
is
t
C
on
se
cu
tiv
e 
 
w
om
en
 w
ith
 P
C
O
S
 
an
d 
in
fe
rti
lit
y 
du
e 
to
 a
no
vu
la
tio
n
N
ot
 re
po
rte
d
A
ge
, e
nd
om
et
ria
l 
th
ic
kn
es
s,
 a
ve
ra
ge
 
in
te
r-
m
en
st
ru
al
 
in
te
rv
al
, m
en
se
s 
bi
op
sy
 in
te
rv
al
, l
as
t 
O
C
 u
se
.
5
C
ym
ba
lu
k 
et
 
al
.(2
00
6)
 [3
1]
, 
P
ol
an
d
H
os
pi
ta
l-b
as
ed
 
ca
se
-c
on
tro
l
14
46
P
os
t -
m
en
op
au
sa
l
56
.3
/5
4.
8[
1]
E
H
 w
ith
 a
ty
pi
a
C
ur
et
ta
ge
 o
r 
hy
st
er
os
co
py
O
be
se
 
po
st
m
en
op
au
sa
l 
w
om
en
 re
fe
rr
ed
 fo
r 
po
st
-m
en
op
au
sa
l 
bl
ee
di
ng
N
ot
 re
po
rte
d
N
ot
 re
po
rte
d
4
E
pp
le
in
 e
t 
al
.(2
00
8)
 [2
7]
,  
U
S
A
P
op
ul
at
io
n-
ba
se
d 
 c
as
e-
co
nt
ro
l
45
44
6
P
re
- a
nd
 p
os
t-
m
en
op
au
sa
l
≥ 
18
C
om
pl
ex
 E
H
 o
r E
H
 
w
ith
 a
ty
pi
a
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
 b
y 
3 
pa
th
ol
og
is
ts
R
an
do
m
ly
 s
el
ec
te
d 
fro
m
 th
e 
sa
m
e 
he
al
th
 p
la
n 
as
 
ca
se
s
N
ot
 re
po
rte
d
M
en
op
au
sa
l s
ta
tu
s,
 
pa
rit
y
7
R
ic
ci
 e
t 
al
.(2
00
2)
 [1
2]
 
Ita
ly
H
os
pi
ta
l-b
as
ed
 
ca
se
-c
on
tro
l
12
9
25
8
P
re
- a
nd
 p
os
t- 
m
en
op
au
sa
l
35
-7
4
C
om
pl
ex
 E
H
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
 
N
on
 
hy
st
er
ec
to
m
iz
ed
 
w
om
en
 s
el
ec
te
d 
fo
rm
 h
os
pi
ta
ls
 
co
ve
rin
g 
th
e 
sa
m
e 
ar
ea
 a
s 
ca
se
s
S
el
f-r
ep
or
te
d,
 
Q
ue
st
io
nn
ai
re
A
ge
, e
du
ca
tio
n
5
S
ha
n 
et
 a
l. 
 
(2
01
4)
 [2
8]
  
C
hi
na
C
ro
ss
-s
ec
tio
na
l
19
4
39
P
re
-m
en
op
au
sa
l
18
-3
5
S
im
pl
e 
or
 c
om
pl
ex
 
E
H
 w
ith
 o
r w
ith
ou
t 
at
yp
ia
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
 
by
 a
t l
ea
st
 2
 
pa
th
ol
og
is
ts
N
ot
 re
po
rte
d
H
ei
gh
t a
nd
 
w
ei
gh
t m
ea
su
re
d 
to
 c
al
cu
la
te
 B
M
I
P
re
gn
an
cy
, s
ev
er
e 
in
fe
ct
io
n,
 C
V
D
, b
re
as
t 
ca
nc
er
, r
ep
ro
du
ct
iv
e 
ca
nc
er
s 
, H
R
T 
us
e,
 
ag
e,
 m
en
op
au
se
7
To
pc
u 
et
 
al
.(2
01
4)
 [3
3]
, 
Tu
rk
ey
R
et
ro
sp
ec
tiv
e 
co
ho
rt
13
20
3
P
re
- a
nd
 
po
st
m
en
op
au
sa
l
41
-6
9/
  4
0-
84
E
H
 w
ith
 o
r w
ith
ou
t 
at
yp
ia
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
N
ot
 re
po
rte
d
N
ot
 re
po
rte
d
N
ot
 re
po
rte
d
7
Vi
ol
a 
et
 a
l.  
(2
00
7)
 [3
2]
, 
B
ra
zi
l
C
ro
ss
-s
ec
tio
na
l
10
17
7
P
re
- a
nd
 
po
st
m
en
op
au
sa
l
18
-7
0
S
im
pl
e 
or
 c
om
pl
ex
 
E
H
 w
ith
 o
r w
ith
ou
t 
at
yp
ia
N
ot
 re
po
rte
d
N
ot
 re
po
rte
d
W
ei
gh
t a
nd
 
he
ig
ht
 m
ea
su
re
d 
to
 c
al
cu
la
te
 B
M
I
S
te
ro
id
 h
or
m
on
e 
us
e,
 ta
m
ox
ife
n 
us
e,
 
hi
st
or
y 
of
 o
va
ria
n 
or
 e
nd
om
et
ria
l 
tu
m
ou
r, 
hi
st
or
y 
of
 
en
do
m
et
rio
si
s
6
Q
ue
te
le
t I
nd
ex
 
K
re
ig
er
 e
t a
l. 
(1
98
6)
 [3
5]
,  
C
an
ad
a
P
op
ul
at
io
n-
ba
se
d 
  c
as
e-
co
nt
ro
l
14
9
24
8
P
re
- a
nd
 p
os
t-
m
en
op
au
sa
l
40
-7
4
A
de
no
m
at
ou
s 
hy
pe
rp
la
si
a
C
on
fir
m
ed
 b
y 
3 
pa
th
ol
og
is
ts
R
an
do
m
ly
 s
el
ec
te
d 
fro
m
 s
am
e 
ne
ig
hb
ou
rh
oo
d 
as
 
ca
se
s
N
ot
 re
po
rte
d
M
en
op
au
sa
l s
ta
tu
s
6
B
od
y 
w
ei
gh
t 
Fa
rq
uh
ar
 e
t 
al
. (
19
99
) [
34
],     
             
N
ew
 Z
ea
la
nd
R
et
ro
sp
ec
tiv
e 
co
ho
rt
46
10
33
P
re
-m
en
op
au
sa
l
17
-5
0
S
im
pl
e 
or
 c
om
pl
ex
 
E
H
 w
ith
 o
r w
ith
ou
t 
at
yp
ia
H
is
to
lo
gi
ca
lly
 
co
nfi
rm
ed
 b
y 
pa
th
ol
og
is
t
N
ot
 re
po
rte
d
P
at
ie
nt
 re
co
rd
 
re
vi
ew
N
ot
 re
po
rte
d
4
Ta
bl
e 
1:
  C
ha
ra
ct
er
is
tic
s 
of
 s
tu
di
es
 in
cl
ud
ed
 in
 th
e 
sy
st
em
at
ic
 re
vi
ew
 o
f E
nd
om
et
ria
l H
yp
er
pl
as
ia
 a
nd
 ri
sk
 fa
ct
or
: b
od
y 
fa
tn
es
s.
Citation: Sanni OB, Kunzmann AT, Murray LJ, McCluggage WG, Coleman HG (2016) Risk Factors (Excluding Hormone Replacement Therapy) for 
Endometrial Hyperplasia: A Systematic Review. Epidemiol 6: 229. doi:10.4172/2161-1165.1000229
Page 5 of 15
Volume 6 • Issue 2 • 1000229
Epidemiol
ISSN: 2161-1165 Epidemiol, an open access journal
 Number of studies included References Pooled risk estimate (95% CI) I-squared (%) p-value
Body mass index
  Unadjusted 6 (12,27-30,32) 1.84 (1.18 – 2.88) 62.9 0.02
  Adjusted, excluding Balbi et al. [29] 6 (12,27,28,30,32,33) 1.20 (0.97 – 1.49) 60.8 0.03
  Adjusted, excluding Ricci et al. [12] 6 (27-30,32,33) 1.88 (1.21 – 2.93) 91.9 0
  Adjusted, excluding Epplein et al. [27] 6 (12,28-30,32,33) 1.78 (1.16 – 2.74) 91.6 0
  Adjusted, excluding Cheung et al. [30] 6 (12,27-29,32,32) 2.29 (1.10 – 4.74) 88.6 0
  Adjusted, excluding Shan et al. [28] 6 (12,27,29,30,32,33) 2.21 (0.96 – 5.07) 91.8 0
  Adjusted, excluding Viola et al. [32] 6 (12,27-30,33) 1.78 (1.19 – 2.67) 91.9 0
  Adjusted excluding Topcu et al. [33] 6 (12,27-30,32) 1.80 (1.19 – 2.71) 91.9 0
  EH without atypia only 3 (12,27,28) 1.27 (0.49 – 3.59) 0 0.9
Smoking 
  Unadjusted 3 (12,27,36) 0.98 (0.64 – 1.49) 45.7 0.16
Diabetes
Unadjusted 3 (12,27,38) 1.43 (0.79 – 2.57) 0 0.96
  Adjusted, excluding Ricci et al. [12] 4 (27,29,33,38) 1.48 (0.47 – 4.64) 46.3 0.13
  Adjusted, excluding Balbi et al. [29] 4 (12,27,33,38) 1.89 (0.82 – 4.37) 40.6 0.17
  Adjusted, excluding Epplein et al. [27] 4 (12,29,33,38) 2.31 (1.10 – 4.85) 11.6 0.34
  Adjusted, excluding Gol et al. [38] 4 (12,27,29,33) 1.89 (0.64 – 5.52) 43.8 0.15
  Adjusted, excluding Topcu et al. [33] 4 (12,27,29,38) 1.37 (0.66 – 2.82) 0 0.43
  EH without atypia only 3 (12,27,38) 1.32 (0.31 – 5.70) 0 0.78
Hypertension
  Unadjusted 3 (12,27,39) 1.33 (0.76 – 2.30) 68.5 0.04
  Atypical EH only 3 (27,38,39) 1.92 (0.57 – 6.53) 70.3 0.04
  EH without atypia only 3 (12,27,38) 1.17 (0.39 – 3.45) 0 0.96
Table 2: Summary of unadjusted, subgroup and sensitivity analyses excluding individual studies from meta-analyses.
Overall  (I-squared = 0.0%, p = 0.435) 
Weir et al, 1994 
Ricci et al, 2002 
Study 
Epplein et al, 2008 
Ever vs Never 
Ever vs Never 
Comparison 
Current vs Never 
0.88 (0.66, 1.17) 
0.80 (0.48, 1.34) 
1.11 (0.70, 1.73) 
OR (95% CI) 
0.72 (0.42, 1.22) 
100.00 
31.20 
39.87 
Weight 
% 
28.93 
    1 .5 .75 1.5 2 
Figure 2: Adjusted meta-analysis for highest versus lowest category of BMI and EH risk.
non-diabetic women (RR 1.43, 95%CI 0.79–2.57; I2=0%). Five studies 
[12,28,30,34,38] were included in meta-analyses to derive adjusted pooled 
EH risk estimate (RR 1.77, 95%CI 0.79–3.96; I2=31.8%), as shown in Figure 
4. Egger’s test showed no significant evidence of publication bias (p=0.34).
While risk estimates remained non-significant for the most part 
of sensitivity analyses, a significant positive association was observed 
when the study by Epplein et al. [28] was excluded. Heterogeneity 
however ranged from low to moderate throughout. Sub-group analysis 
by EH type showed non-significant positive association between EH 
without atypia and diabetes (RR 1.32, 95%CI 0.31-5.70) (Table 2). Two 
studies reported adjusting for BMI while none adjusted for HRT use as 
shown in Table 5. 
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Risk factor No. of studies References Study design Summary of results
Body weight 1 34 Retrospective cohort n=1 study reported increased risk of complex EH with atypia amongst women weighing ≥90kg when compared with women weighing <90kg.
Quetelet index 1 35 Population-based case-control n=1 study reported significant higher waist-hip ratio in EH cases when compared with controls.
Physical activity 1 29 Hospital-based case-control
n=1 study reported non-significant increased risk of EH amongst women who reported higher levels 
of physical activity.
History of cancer
 
2
 
12,34
 
1 hospital-based 
case-control, 
1 retrospective 
cohort study
n=1 study reported non-significant 20% reduced risk of EH amongst women with a family history of 
EC.
n=1 study reported significant increased risk of EH amongst women with a family history of EC or 
colon cancer
Oral contraceptive 
use
 
2
 
12,27
 
1 population-based 
case-control, 1 
hospital-based case-
control 
 
n=1 study reported a reduced risk of complex and atypical EH amongst women used OC 6months 
prior to abnormal vaginal bleeding.
n=1 study reported non-significant increased risk of EH amongst women who had ever used OC 
compared with never-users.
Parity
 
2
 
12,27
 
1 population-based 
case-control, 1 
hospital-based case-
control 
 
n=1 study reported significant reduced risk of EH amongst women who had given birth to 3 or more 
children in comparison with women who had never given birth.
n=1 study reported non-significant increase in risk of EH amongst women who had given birth to 2 
or more children in comparison with nulliparous women.
Nulliparity
 
2
 
34,37
 
1 hospital-based 
case-control, 1 
retrospective cohort 
study
 
n=1 study reported significant increased risk of EH or EC amongst nulliparous women in 
comparison with multiparous women.
n=1 study reported significant increased risk of EH amongst nulliparous women in comparison with 
multiparous women
Menopausal status
 
2
 
12,28
 
1 hospital-based 
case-control, 1 
cross-sectional study
 
n=1 study reported a non-significant reduced risk of non-atypical EH among post-menopausal 
women when compared with pre-menopausal women but non-significant increased risk of atypical 
EH was reported for postmenopausal women compared with pre-menopausal women.
n=1 study reported a significant reduced risk of complex amongst post-menopausal women in 
comparison with pre- and peri-menopausal women.
Education and 
Income
 
2
 
12,35
 
1 hospital-based 
case-control, 1 
population-based 
case-control study
n=1 study reported higher level of education amongst EH cases compared with controls.
n=1 study reported higher income for EH cases compared with controls.
Age
 
2
 
12,37
 
2 hospital-based 
case-control studies
 
n=1 study reported significant increased risk of EH or EC amongst women ≥70 years compared 
with women 49-59 years old.
n=1 study reported non-significant reduced risk of EH amongst women ≥65years in comparison with 
women <45years old.
Table 3: Summary of results for risk factors for EH for which meta-analyses were not possible.
Hypertension
Four studies [12,28,30,39] reported on hypertension in relation to 
EH risk. Characteristics of the studies are shown in Table 5.
Three studies [12,28,39] were included in meta-analysis to derive an 
unadjusted pooled risk estimate of OR 1.33 (95%CI 0.76–2.30; I2=68.5%), 
and four studies [12,28,30,39] were included in meta-analysis to derive 
adjusted pooled risk estimate of OR 1.51 (95%CI 0.72–3.15; I2=79.1%) for 
hypertensive versus normotensive women (Figure 5). Egger’s test showed 
no significant evidence of publication bias (p=0.28).
Sub-group analyses showed non-significant positive associations 
between atypical EH (RR 1.92 95%CI 0.57-6.53) and EH without atypia 
(RR 1.17 95%CI 0.39-3.45) (Table 2) and hypertension status; only the 
latter showed reduced heterogeneity. Two studies adjusted for BMI 
while one reported adjusting for HRT as shown in Table 5.
Family History of cancer
Women with a family history of endometrial cancer were reported 
by Ricci et al. [12] to have around 20 percent reduced risk of developing 
EH , although not statistically significant (OR 0.8 95% CI 0.2 –2.6). 
Another study found women with abnormal bleeding who had a family 
history of colon cancer or endometrial cancer to be more likely to 
develop endometrial cancer or complex EH with atypia (OR 9.1, 95%CI 
2.2 – 37.1;OR 5.8, 1.1 – 28.6, respectively) [35]. (Tables 1 and 5). None 
of the studies reported adjusting for BMI or HRT use as shown in Table 
5.
Reproductive factors
Oral contraceptive use
Two studies [12,40] examined the relationship between oral 
contraceptive use and the risk of developing EH (Table 6). One 
population-based case-control study reported a reduced risk of 
complex and atypical EH among women who had used OC 6 months 
before presenting with abnormal bleeding (OR 0.2, 95%CI 0.0–0.6) after 
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Author, 
Year, 
Location
Study 
design
No. 
Cases
No. 
Controls/
cohort 
size
Menopausal 
status
Age, 
years 
(range) 
Cases/ 
Controls
Case 
definition 
including EH 
type
Method of 
diagnosis Control definition
Method of 
measuring 
body fatness
Adjusted 
confounders
Quality 
scale 
score 
(max. 
9)
Smoking 
Epplein 
et 
al.(2008) 
[27], 
USA
Population-
based  
case-
control
45 446
Pre- and 
post-
menopausal
≥ 18
Complex EH 
or EH with 
atypia
Histologically 
confirmed 
by 3 
pathologists
Randomly selected 
from the same health 
plan as cases
Medical record 
review
Menopausal 
status, BMI, 
parity
7
Ricci et 
al.(2002) 
[12],  
Italy
Hospital-
based 
case-
control
129 258
Pre- and 
post- 
menopausal
35-74 Complex EH Histologically confirmed 
Non hysterectomized 
women selected form 
hospitals covering the 
same area as cases
Self-reported, 
Questionnaire Age, education 5
Weir et 
al.(1994) 
[36], 
Canada
Population-
based 
case-
control
177 530
Pre- and 
post-
menopausal
40-74 Adenomatous hyperplasia
Histologically 
confirmed 
by 3 
pathologists
Randomly selected 
from same 
neighbourhood as 
cases
Interview Age, obesity, oestrogen use 6
Physical activity 
Balbi et 
al.(2012) 
[29],  
Italy
Hospital-
based 
case-
control
167 282 Pre-menopausal 40-55 Simple EH
Confirmed by 
1 pathologist
Women attending 
gynaecologic unit of 2 
hospitals for menstrual 
irregularities
Interview, 
medical history, 
general physical 
examination
Age, 
hypertension, 
BMI, diabetes
7
Table 4:  Characteristics of studies included in the systematic review of Endometrial Hyperplasia and risk factor: smoking and physical activity.
Overall  (I-squared = 0.0%, p = 0.435) 
Weir et al, 1994 
Ricci et al, 2002 
Study 
Epplein et al, 2008 
Ever vs Never 
Ever vs Never 
Comparison 
Current vs Never 
0.88 (0.66, 1.17) 
0.80 (0.48, 1.34) 
1.11 (0.70, 1.73) 
OR (95% CI) 
0.72 (0.42, 1.22) 
100.00 
31.20 
39.87 
Weight 
% 
28.93 
    1 .5 .75 1.5 2 
Figure 3: Adjusted meta-analysis for highest versus lowest category of smoking and EH risk.
adjusting for BMI. However, a non-significant increased risk of EH was 
found in another study among women who had ever used OC versus 
those who had never used OC (OR 1.6, 95%CI 0.9–2.8) [12] (Table 1). 
The authors further assessed OC use and EH risk by duration of use and 
consistently found non-significant increased risks when they compared 
women who had used OC for more than 5 years, 13–60 months, 12 
years or less with never users (OR 1.2, 95%CI 0.4–3.4;OR 1.4, 95%CI 
0.5–3.6; and OR 2.0, 0.9–4.3, respectively). It should however be noted 
that BMI or HRT use was not adjusted for in the latter as shown in Table 6.
Parity
When comparing women who had given birth to two or more babies 
with nulliparous women, Ricci et al. [12] found an almost significant 
2-fold (OR 1.8, 95%CI 0.9–3.6) increase in risk of complex EH (Table 
1) after adjusting for age and education [12]. In contrast, Epplein et 
al. [28], found significant reduced risk (OR 0.29, 95% CI 0.07–0.51) of 
EH among women who had given birth to three or more babies when 
compared with nulliparous women, after adjusting for BMI [28].
Two studies which compared nulliparous women with multiparous 
women found a significant increased risk of EH in nulliparous women 
(OR 3.7, 95%CI 1.2-10.9) 35 and (OR 2.8, 95% CI 1.3-6.1) (after 
adjusting for prior use of oestrogen) [41], respectively. Meta-analysis 
was not performed for these four studies, summarised in Table 6, due 
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Figure 4: Adjusted meta-analysis comparing women with hypertension with normotensive women in relation to EH risk.
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Figure 5: Adjusted meta-analysis comparing women with hypertension with normotensive women in relation to EH risk.
to differences in the reference groups analysed. While two studies 
Farquhar et al and Feldman et al used multiparous women as reference 
group, Epplein et al and Ricci et al. [12] used nulliparous women as 
reference group.
Menstrual history
Menopausal status
Two hospital-based case-control studies [12,29] evaluated 
menopausal status in relation to EH risk (Table 6). One study among 
Chinese women 29 found that postmenopausal women were less 
likely to develop EH without atypia (OR 0.65, 95%CI 0.17–2.50) but 
they were more likely to develop EH with atypia (OR 2.40, 95%CI 
0.43–13.27) when compared with premenopausal women, although 
these estimates did not achieve statistical significance. Similarly, 
another study 12 also reported a significant reduced risk of complex 
EH among postmenopausal women in comparison with pre- and peri-
menopausal women (OR 0.2, 95%CI 0.1–0.5). The authors also found 
a non-significant 20% increased risk of complex EH among women 
who reported menopause at ≥53 years versus <50 years at menopause 
[12] (Table 1). One of the studies reported adjusting for BMI and HRT 
use as shown in Table 6. One further study suggested that polycystic 
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ovarian syndrome patients with longer intermenstrual intervals have 
a significant increased risk of developing EH (OR 1.43, 95%CI 1.78-
1.15) after adjusting for confounders including last oral contraceptive 
use [31].
Other factors
Age
Two hospital-based case-control studies reported risk estimates for 
age with regards to EH [12,41]. Characteristics and results from these 
studies are shown in Tables 1 and 7 . One study reported a significant 
increased risk of EH or EC amongst women ≥70 years old versus women 
49-59 years old after adjusting for confounders including prior use of 
oestrogen, and another study reported a non-significant decreased 
risk of EH amongst women ≥65 years old versus <45 years old. Meta–
analyses were not conducted because only two studies [12,41] provided 
risk estimates for age in relation to development of EH, reports from the 
studies were mixed (Table 1). One of the studies adjusted for quetelet 
index, a measure of body fatness as shown in . 
Socio-economic status
Two studies [12,36] examined education and income in relation 
to EH risk (Table 7). In one study, a positive association was observed 
among women who had ≥12 compared with <7 years of education (OR 
2.8 95% CI 1.70–4.80).
Similarly, women who earned ≥$30,000 were found to have higher 
chances of developing EH when they were compared with women who 
earned less than $30,000 in a Canadian study (Table 1). The observed 
association was significant for premenopausal women (OR 1.85, 95%CI 
1.16 – 2.96) but not for postmenopausal women (OR 1.15, 95%CI 0.78 
– 1.69) [36]. Neither of the studies reported adjusting for HRT use or 
BMI as shown in Table 7.
Comment
Main findings
In this novel systematic review of risk factors for EH (excluding 
hormone replacement therapies), meta-analyses suggested a significant 
positive association between increased BMI and risk of EH; no 
significant associations were detected between smoking, hypertension 
or diabetes and EH risk in pooled analyses of a limited number of 
studies. However, there was paucity of high quality, consistent evidence 
for the aforementioned and other factors in the review. There was also 
inadequate adjustment for relevant confounders, namely HRT and 
BMI, in some of the included studies.
The importance of pooling risk estimates is demonstrated by the 
expected finding that higher BMI is positively associated with EH 
compared with lower BMI, considering that only three out of six 
studies which reported a positive association between BMI and EH risk 
showed statistical significance. EH is an oestrogen-driven disease. From 
a biologically plausible viewpoint, it is well known that oestrogen can 
be synthesized from adipose tissue, this increases the level of circulating 
oestrogen which in turn stimulates growth of the endometrium. 
Reduction in high heterogeneity which occurred when the study of 
simple EH 30 was excluded during sensitivity analyses suggests that the 
relationship between BMI and EH may differ according to the presence 
of atypia.  Due to the role of body fatness in the development of EH and 
endometrial cancer, it is important for women to maintain a healthy 
weight [15].
Pooled analysis of studies that investigated hypertension showed 
non-significant positive association between hypertension and EH risk. 
Some authors have reported that hypertension is positively associated 
with EH 40 or endometrial cancer [42]. However, this association 
was found among overweight or obese women compared with lean 
women [42], this observation should therefore be viewed with caution 
as it is likely to be confounded, considering the association between 
obesity and hypertension. Hypertension has previously been linked 
to insulin-like growth factor 1 (IGF-1), and measures of body fatness 
such as waist-hip ratio and obesity were reported to be higher among 
hypertensive patients than controls [43,44]. IGF-1 is known to be 
related to cell growth and cancer progression [45]. 
We found a non-significant increased EH risk among diabetic 
versus non-diabetic women. Although the mechanism for a potential 
association between diabetes and EH is not very clear, diabetes has been 
linked to IGF-1 [46]. Low levels of IGF-1were found to be positively 
associated with diabetes after adjusting for confounders including BMI 
[46]. In a rat model, Type 1 diabetes was also been shown to induce EH 
development, potentially mediated by oestrogen receptor alpha and p16 
expression [47]. Several authors have reported overweight/obesity as 
one of the most important modifiable risk factors for diabetes [48,49]. 
Despite the well-known relationship between obesity and diabetes, few 
of the studies included in our meta-analysis adequately adjusted for this 
confounder.
Meta-analysis of three studies showed no association between 
tobacco smoking and risk of EH. An earlier literature review suggested 
that smoking has an anti-oestrogenic effect, which can reduce the rate 
of androgen-oestrogen conversion [50]. Smoking has also been linked 
to early menopause [51-53]. Women who undergo menopause early are 
less exposed to oestrogen than women who are older at menopause. 
However, smoking has been consistently linked to the development of 
many neoplastic conditions and is certainly not advised [54,55]. It is 
plausible that known carcinogenic effects of smoking may be countered 
by the aforementioned anti-oestrogenic effect, explaining the observed 
null association for tobacco smoking and EH risk. 
One study reported a non-significant increased EH risk for women 
with self-reported higher levels of physical activity compared to those 
who reported lower levels of physical activity. However, as with all self-
reported information of desirable lifestyle factors, this result should be 
interpreted with caution. Physical activity has previously been shown 
to be protective against endometrial carcinoma, given that physical 
activity may modulate metabolism, and excretion of endogenous sex 
hormones such as oestrogen which is also known to be responsible for 
development of EH [56]. Interestingly the previously described EH 
diabetic rat model did observe a significant reduction in oestrogen-
receptor alpha and p16 expression for those rats undertaking aerobic 
exercise [48]. 
Contrasting results were reported for parity and EH risk by 
individual studies included in this review, although the majority 
reported protective effects of child-bearing for EH risk. Nulliparity is 
known to be associated with an increased risk of endometrial cancer 
[57] - a possible mechanism for this is that during pregnancy, a woman 
is exposed to larger amounts of progesterone as opposed to oestrogen. 
Contrasting reports were also observed for the two studies investigating 
OC use and EH risk. It should however be noted that OC usage has 
consistently been found to reduce EC risk among users when compared 
with non-users [58,59]. Biologically, this is related to the low dose of 
oestrogen in relation to progestin contained in OC, which inhibits 
endometrial proliferation [60,61].
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A significant decreased risk of complex EH was reported among 
postmenopausal versus pre- and peri-menopausal in an Italian study. 
Conversely, findings from a further study included in our review 
suggesting an increased risk of atypical EH among postmenopausal 
versus premenopausal women, which may indicate that HRT use, 
a well-known risk factor for EH, has more of a propensity to invoke 
atypical than non-atypical EH. We however did not assess use of HRT 
in this review due to an earlier Cochrane review which assessed the 
effects of different hormone therapy regimens on the postmenopausal 
endometrium. The reviewers found unopposed oestrogen to be 
associated with increased risk of all types of EH at all doses, in line with 
the existing literature. Although the reviewers did not perform sub-
group analysis for the different types of EH, they found no difference in 
the risk of EH in women who took low dose oestrogen combined with 
progestogen compared with controls who took placebo [13]. 
It is notable that one study reported an increased risk of complex 
EH in women with higher versus lower level of education while 
another reported the same association amongst women with higher 
versus lower income. Measures of social class have been implicated in 
the development of neoplasms due to the differing medical attention 
seeking behaviour of the different groups [62,63].
Finally, two studies in the review suggest a link between family 
history of endometrial or colon cancer in relation to EH risk. This points 
to a shared genetic or environmental risk factor in EH development. 
Families with a history of Lynch syndrome have been found to have 
between 1.5–3 fold increased risk of developing endometrial cancer 
[64]. Indeed endometrial cancer is more common than colonic cancer 
in patients with Lynch syndrome.
Strengths and limitations
This is the first systematic review examining the risk factors 
(excluding HRT use) for EH, the review has a number of strengths and 
limitations. A major strength of this review was the evaluation of three 
databases and the robust methodology and adherence to a previously 
published protocol. This included the strict exclusion of several studies 
that included simple EH cases in control groups. Although several 
studies that were included reported on EH combined with other 
outcomes such as benign endometrial polyps and/or carcinoma, we 
were careful to consider those separately in our interpretations, as their 
risk estimates would be distorted. We were also able to perform sub-
group analyses for atypical and non-atypical EH in relation to BMI, 
diabetes and hypertension. Importantly, our collective assessment of 
EH risk factors has highlighted the general paucity of data available for 
this condition, but does suggest that EH could be potentially prevented 
through maintenance of normal body weight.
Limitations of this systematic review largely relate to insufficient 
data which would have been helpful in increasing precision of risk 
estimates for the different risk factors evaluated. Pooled risk estimates 
could not be derived for important risk factors such as age, parity and 
menopausal status due to insufficient number of studies (<3) providing 
risk estimates, in accordance with our protocol. Also, many hospital-
based studies were included, which limits applicability of results to 
the general population. In addition, very few studies adjusted for HRT 
use and BMI in their statistical models. HRT use is known to play a 
significant role in the development of EH, its use at all doses in the 
treatment of menopausal symptoms has been found to be associated 
with an increased risk of EH [65]. It is still plausible that additional risk 
factors may exist for EH and could be identified in future, high-quality 
studies.
The relationship between a high BMI and EH cannot be 
overemphasized as is shown in this review. Notably, no studies evaluated 
nutrition or dietary factors in relation to EH risk, even though several 
aspects of diet, for example coffee and high glycaemic load intake, have 
been associated with endometrial cancer risk [15]. We hope that this 
review stimulates further work in this area in an effort to identify more 
modifiable, preventative factors for EH.
Conclusions 
In conclusion, body fatness was found to be associated with an 
increased risk of EH, therefore women should be encouraged to 
maintain a normal body weight. No significant associations were 
detected for other factors and EH risk. However, relatively few studies 
have been conducted and further aetiological studies which might help 
identify other non-modifiable risk factors for EH are warranted.
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